New hope for Drug-Resistant lung cancer: experimental pill enters human trials
NCT ID NCT06567015
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral drug, STX-241, in people with advanced non-small cell lung cancer that has become resistant to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial aims to find the safest and most effective dose while monitoring side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Hôpital de la Timone
RECRUITINGMarseille, 13385, France
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
-
Centro Intergral Oncologico Clara Campal (CIOCC) (START Madrid)
RECRUITINGMadrid, 28050, Spain
-
Gustave Roussy
RECRUITINGVillejuif, 94800, France
-
Hospital Universitario La Paz
RECRUITINGMadrid, 28046, Spain
-
Institut Universitaire du Cancer de Toulouse - Oncopole
RECRUITINGToulouse, 31059, France
-
Institut de Cancérologie de l'Ouest (ICO) - René Gauducheau
RECRUITINGSaint-Herblain, 44800, France
-
National Taiwan University Hospital
RECRUITINGTaipei, 10002, Taiwan
-
Netherlands Cancer Institute
RECRUITINGAmsterdam, 1066 CX, Netherlands
-
Oncology Consultants (OC) - Texas Medical Center - Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)
RECRUITINGNashville, Tennessee, 37203, United States
-
Shanghai East Hospital, Tongji University
RECRUITINGShanghai, 200120, China
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 11217, Taiwan
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, 300060, China
-
Universitätsklinikum Carl Gustav Carus Dresden
RECRUITINGDresden, 1307, Germany
-
Vall d'Hebron Institut d'Oncologia
RECRUITINGBarcelona, 8035, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
- Smart patch and app aim to boost lung recovery after cancer surgery
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Custom-Made vaccine aims to stop lung cancer recurrence
- Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
- New study aims to tame cholesterol side effect of lung cancer drug